Ny Chief Development Officer till AnaCardio

AnaCardio AB announces the appointment of Elin Rosendahl, MSc as Chief Development Officer (CDO). Elin has more than 20 years of experience in managing global biopharmaceutical development programs and leading global cross-functional teams in both small and large pharma companies, and joins AnaCardio from her previous role as Vice President, Clinical Development at Vicore Pharma AB.

Elin Rosendahl.

I am pleased to welcome Elin to our growing AnaCardio team. Her extensive leadership skills and profound knowledge in clinical development will be a great asset for AnaCardio and the AC01 program going forward.”, commented Patrik Strömberg, CEO.

Elin Rosendahl said: ”I am very excited to join the AnaCardio team in this important phase of development. The lead development program, AC01, explores a novel and unique mode of action with the potential to transform the treatment of patients with heart failure”.